Last reviewed · How we verify
Tyrosine kinase inhibitor
Tyrosine kinase inhibitors block the activity of specific enzymes called tyrosine kinases, which are involved in the activation of proteins by signal transduction cascades.
Tyrosine kinase inhibitors block the activity of specific enzymes called tyrosine kinases, which are involved in the activation of proteins by signal transduction cascades. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Chronic myeloid leukemia.
At a glance
| Generic name | Tyrosine kinase inhibitor |
|---|---|
| Also known as | Study treatment, Protein Tyrosine Kinase Inhibitors, PTK Inhibitors, TK Inhibitors, TKI |
| Sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Drug class | Tyrosine kinase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tyrosine kinases are enzymes responsible for the activation of proteins by signal transduction cascades. By inhibiting these enzymes, tyrosine kinase inhibitors can prevent the growth and spread of cancer cells. This class of drugs is often used in the treatment of various types of cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Chronic myeloid leukemia
Common side effects
- Diarrhea
- Rash
- Fatigue
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (PHASE2)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (PHASE1)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: